Loncastuximab Tesirine
Primary Central Nervous System Lymphoma
Explore 71 assets in Primary Central Nervous System Lymphoma →Floatz Rating
CC41/100
Confidence
Indicative
Sponsor
University of Utah
Modality
antibody_drug_conjugate
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06607549CT.gov Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Central Nervous System Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Loncastuximab Tesirine (this asset) | University of Utah | P1 | CC · 41 |
| Etoposide | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P4 | BBB |
| (+)-Vincristine | Ono Pharmaceutical Co., Ltd. | P4 | BBB |
| Adriamycin | Juan P. Alderuccio, MD | P4 | BB |
| Idarubicin | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P4 | BB |
| Orelabrutinib | The First Affiliated Hospital with Nanjing Medical University | P3 | BB |
| Rituximab | Ono Pharmaceutical Co., Ltd. | P4 | BB |
| Dexasone | Allison Winter | P4 | BB |
| Cytarabine | The Lymphoma Academic Research Organisation | P4 | BB |
+42 more in the Primary Central Nervous System Lymphoma cohort
Other indications for Loncastuximab Tesirine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Non-Hodgkin Lymphoma | — | P2/3 | B · 61 |
| Marginal Zone Lymphoma | — | P2 | CCC · 55 |
| Relapsed/Refractory Diffuse Large B-Cell Lymphoma | — | P3 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- EtoposideFederal Research Institute of Pediatric Hematology, Oncology and ImmunologyBBB
- (+)-VincristineOno Pharmaceutical Co., Ltd.BBB
- AdriamycinJuan P. Alderuccio, MDBB
- IdarubicinFederal Research Institute of Pediatric Hematology, Oncology and ImmunologyBB
- OrelabrutinibThe First Affiliated Hospital with Nanjing Medical UniversityBB
Citation
Floatz Terminal. Loncastuximab Tesirine in Primary Central Nervous System Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/loncastuximab-tesirine-primary-central-nervous-system-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →